Heim8QQ • FRA
add
AbCellera Biologics Inc
Við síðustu lokun
1,78 €
Dagbil
1,78 € - 1,78 €
Árabil
1,70 € - 3,79 €
Markaðsvirði
588,01 m. USD
Meðalmagn
448,00
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 4,24 m. | -57,45% |
Rekstrarkostnaður | 24,40 m. | -4,55% |
Nettótekjur | -45,62 m. | -12,34% |
Hagnaðarhlutfall | -1,08 þ. | -164,04% |
Hagnaður á hvern hlut | -0,15 | -7,14% |
EBITDA | -57,33 m. | -14,54% |
Virkt skatthlutfall | 13,90% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 605,27 m. | -13,29% |
Heildareignir | 1,34 ma. | -8,13% |
Heildarskuldir | 321,23 m. | -3,59% |
Eigið fé alls | 1,02 ma. | — |
Útistandandi hlutabréf | 298,48 m. | — |
Eiginfjárgengi | 0,52 | — |
Arðsemi eigna | -11,58% | — |
Ávöxtun eigin fjár | -14,16% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -45,62 m. | -12,34% |
Handbært fé frá rekstri | -11,55 m. | 72,30% |
Reiðufé frá fjárfestingum | 7,94 m. | -73,47% |
Reiðufé frá fjármögnun | 5,97 m. | 110,88% |
Breyting á handbæru fé | 2,94 m. | 130,17% |
Frjálst peningaflæði | -63,60 m. | -21,59% |
Um
AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization that is contracted by biotechnology and pharmaceutical companies for antibody services, and researches and develops human antibodies as a service for its clients. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
Framkvæmdastjóri
Stofnsett
2012
Höfuðstöðvar
Vefsvæði
Starfsfólk
596
